BRPI0810949A2 - "método de preparação de células multipotentes, auto-renovadoras, diferenciadoras ou resistentes a doenças, célula e vetor pra uso do método" - Google Patents

"método de preparação de células multipotentes, auto-renovadoras, diferenciadoras ou resistentes a doenças, célula e vetor pra uso do método"

Info

Publication number
BRPI0810949A2
BRPI0810949A2 BRPI0810949A BRPI0810949A BRPI0810949A2 BR PI0810949 A2 BRPI0810949 A2 BR PI0810949A2 BR PI0810949 A BRPI0810949 A BR PI0810949A BR PI0810949 A BRPI0810949 A BR PI0810949A BR PI0810949 A2 BRPI0810949 A2 BR PI0810949A2
Authority
BR
Brazil
Prior art keywords
renewing
differentiating
vector
self
cell
Prior art date
Application number
BRPI0810949A
Other languages
English (en)
Inventor
Christopher B Reid
Original Assignee
Christopher B Reid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christopher B Reid filed Critical Christopher B Reid
Publication of BRPI0810949A2 publication Critical patent/BRPI0810949A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
BRPI0810949A 2007-05-29 2008-05-28 "método de preparação de células multipotentes, auto-renovadoras, diferenciadoras ou resistentes a doenças, célula e vetor pra uso do método" BRPI0810949A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US93202007P 2007-05-29 2007-05-29
US93313307P 2007-06-05 2007-06-05
US93367007P 2007-06-08 2007-06-08
US644908P 2008-01-14 2008-01-14
US6476108P 2008-03-25 2008-03-25
PCT/US2008/065007 WO2008150814A2 (en) 2007-05-29 2008-05-28 Methods for production and uses of multipotent cell populations

Publications (1)

Publication Number Publication Date
BRPI0810949A2 true BRPI0810949A2 (pt) 2015-10-27

Family

ID=40094346

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810949A BRPI0810949A2 (pt) 2007-05-29 2008-05-28 "método de preparação de células multipotentes, auto-renovadoras, diferenciadoras ou resistentes a doenças, célula e vetor pra uso do método"

Country Status (15)

Country Link
US (1) US20110217274A1 (pt)
EP (2) EP3128015A3 (pt)
JP (2) JP2010528613A (pt)
CN (2) CN101772580B (pt)
AU (1) AU2008260187A1 (pt)
BR (1) BRPI0810949A2 (pt)
CA (1) CA2725953A1 (pt)
ES (1) ES2612538T3 (pt)
HU (1) HUE030872T2 (pt)
IL (2) IL202401A (pt)
PL (1) PL2164993T3 (pt)
PT (1) PT2164993T (pt)
RU (2) RU2535365C2 (pt)
SG (2) SG10201509679XA (pt)
WO (1) WO2008150814A2 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
EP2137296A2 (en) 2007-03-23 2009-12-30 Wisconsin Alumni Research Foundation Somatic cell reprogramming
US11859168B2 (en) * 2007-05-29 2024-01-02 Christopher B. REID Electroporation, developmentally-activated cells, pluripotent-like cells, cell reprogramming and regenerative medicine
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
EP2268809B1 (en) 2008-05-02 2019-02-06 Kyoto University Method of nuclear reprogramming
EP3112456A1 (en) 2008-06-04 2017-01-04 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
KR101773345B1 (ko) * 2008-08-12 2017-08-31 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 ｉＰＳ 세포의 생산 방법
JP2010148440A (ja) * 2008-12-25 2010-07-08 Japan Health Science Foundation 組換えアデノウイルス迅速構築システム
US8728458B2 (en) 2009-04-30 2014-05-20 The Regents Of The University Of California Combination anti-HIV vectors, targeting vectors, and methods of use
US9365866B2 (en) * 2009-06-03 2016-06-14 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
US9453205B2 (en) * 2009-10-31 2016-09-27 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
JP2013534525A (ja) * 2010-06-23 2013-09-05 ヴィヴォスクリプト，インコーポレイテッド 心臓疾患の治療のために遺伝子改変を伴わずに細胞を再プログラミングするための組成物および方法
CA2817191A1 (en) 2010-10-08 2012-04-12 Pal Saetrom Short rna molecules
WO2012061075A2 (en) * 2010-10-25 2012-05-10 The Regents Of The University Of California Hiv resistant and functional hematopoietic stem/progenitor cells and macrophages from induced pluripotent stem cells
JP6073795B2 (ja) * 2010-10-27 2017-02-01 カッパーアールエヌエー，インコーポレイテッド インターフェロン関連発生制御因子１（ｉｆｒｄ１）への天然アンチセンス転写物の阻害によるｉｆｒｄ１関連疾患の治療
RU2691027C2 (ru) * 2011-12-05 2019-06-07 Фэктор Байосайенс Инк. Способы и препараты для трансфекции клеток
CN102659951A (zh) * 2012-05-29 2012-09-12 西安医学院 一种TAT结构域修饰的neurogenin2融合蛋白制备方法和用途
WO2014035433A1 (en) * 2012-08-31 2014-03-06 Jan Nolta Genetically modified msc and therapeutic methods
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
JP6621409B2 (ja) 2013-11-22 2019-12-18 ミナ セラピューティクス リミテッド Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物
CN115323000A (zh) * 2015-03-09 2022-11-11 西奈卫生系统公司 使用细胞分裂基因座控制细胞增殖的工具和方法
US11576965B2 (en) 2015-07-02 2023-02-14 Medigen, Inc. Recombinant bovine immunodeficiency virus gag virus-like particles containing influenza immunogens
WO2017007994A1 (en) * 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
CN106338423B (zh) 2015-07-10 2020-07-14 三斯坎公司 组织学染色的空间复用
TWI808934B (zh) 2015-12-31 2023-07-21 美商伯克利之光生命科技公司 經工程化以表現促發炎多肽之腫瘤浸潤細胞
WO2017160991A1 (en) * 2016-03-16 2017-09-21 Lavieu Gregory G Methods, systems and devices for selection and generation of genome edited clones
US11013752B2 (en) 2016-06-03 2021-05-25 Hough Ear Institute Combination therapies for inner ear sensory hair cell regeneration/replacement
CN106086075B (zh) * 2016-06-23 2019-08-06 福建医科大学 CXCR4RNAi慢病毒载体的构建方法
EP3488005A4 (en) * 2016-07-19 2020-07-29 University of Pittsburgh- Of the Commonwealth System of Higher Education TARGETING ONCOLYTIC VIRUSES STAT3
CN106497882A (zh) * 2016-10-29 2017-03-15 复旦大学 同时过表达R‑spondin1和Noggin的细胞株及其构建方法和应用
CN110546495B (zh) 2016-12-30 2022-11-01 加利福尼亚州立大学董事会 用于基因组编辑t细胞的选择和传代的方法
CN108977463A (zh) * 2017-05-31 2018-12-11 伯仕利生物科技发展（盐城）有限公司 一种用于抑制生产用干细胞分化的技术方法
US20210363486A1 (en) * 2018-02-09 2021-11-25 Kyoto University Cardiomyocyte proliferation promoting agent and use thereof
WO2019165320A1 (en) * 2018-02-22 2019-08-29 Celularity, Inc. Post partum tissue-derived induced pluripotent stem cells and uses thereof
CN108715868A (zh) * 2018-05-31 2018-10-30 深圳市免疫基因治疗研究院 一种Gaucher慢病毒载体、慢病毒及其制备方法和应用
CN111484977B (zh) * 2019-01-25 2023-05-16 中国科学院脑科学与智能技术卓越创新中心 重编程产生功能性去甲肾上腺素能神经元的方法
CN110283779A (zh) * 2019-07-17 2019-09-27 吉林省农业科学院 一种鸡胚胎干细胞的分离培养方法及培养基
CA3197320A1 (en) * 2020-09-29 2022-04-07 NeuExcell Therapeutics Inc. Dlx2 vector
CN118086341A (zh) * 2024-04-25 2024-05-28 上海凌医生物科技有限公司 在肝脏中高表达人源葡萄糖脑苷脂酶基因的表达框

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2395698A (en) 1943-12-18 1946-02-26 Walter J Mathieu Electric switch
US4361552A (en) 1980-09-26 1982-11-30 Board Of Regents, The University Of Texas System Wound dressing
US5032508A (en) 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4902508A (en) 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
US4956178A (en) 1988-07-11 1990-09-11 Purdue Research Foundation Tissue graft composition
JP2710967B2 (ja) * 1988-11-22 1998-02-10 株式会社日立製作所 集積回路装置の製造方法
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US5281422A (en) 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
ATE301201T1 (de) 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
US6217867B1 (en) 1993-09-13 2001-04-17 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
US6432711B1 (en) * 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
WO1996017073A1 (fr) 1994-11-29 1996-06-06 Takara Shuzo Co., Ltd. Procede pour la production de cellules transformees
US5554389A (en) 1995-04-07 1996-09-10 Purdue Research Foundation Urinary bladder submucosa derived tissue graft
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
GB9518606D0 (en) * 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
US5783566A (en) 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
AU742457B2 (en) 1996-08-23 2002-01-03 Cook Biotech, Incorporated Graft prosthesis, materials and methods
DE69734218T2 (de) 1996-12-10 2006-07-06 Purdue Research Foundation, West Lafayette Gewebetransplantat aus der Magensubmukosa
DE69827001T2 (de) 1997-04-11 2005-09-08 Cryolife, Inc. Gewebedezellularization
EP1017797B1 (en) * 1997-09-24 2005-06-22 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
US6734018B2 (en) 1999-06-07 2004-05-11 Lifenet Process for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced
MXPA02000128A (es) 1999-06-22 2002-06-21 Res Dev Foundation Material mejorado de heridas para mejorar curacion de heridas.
US6376244B1 (en) 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US6479064B1 (en) 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
EP1315796B1 (en) 2000-08-16 2006-07-12 Duke University Decellularized tissue engineered constructs and tissues
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU2001292917A1 (en) 2000-09-20 2002-04-02 Regeneration Technologies, Inc. Method of preparing and processing transplant tissue
US6995013B2 (en) 2002-07-08 2006-02-07 Biomed Solutions, Llc Cell-scaffold composition containing five layers
US7211247B2 (en) 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
CA2452033C (en) 2001-06-28 2011-11-08 Cook Biotech Incorporated Graft prosthesis devices containing renal capsule collagen
WO2003020191A1 (en) 2001-09-04 2003-03-13 University Of Iowa Research Foundation Cellulose membranes for biodegradable scaffolds
US20030109037A1 (en) * 2001-09-24 2003-06-12 Reid Christopher Brian Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease
US20030099621A1 (en) 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
US7297540B2 (en) 2002-01-15 2007-11-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs
AU2003211066A1 (en) 2002-02-19 2003-09-09 Bioarttis, Inc. Artificial vessel scaffold and artificial organs therefrom
AU2004206232A1 (en) * 2003-01-17 2004-08-05 University Of Florida Research Foundation Inc. Small interference RNA gene therapy
CA2618731C (en) 2005-08-26 2021-12-28 Regents Of The University Of Minnesota Decellularization and recellularization of organs and tissues
EP2206724A1 (en) * 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor

Also Published As

Publication number Publication date
RU2718536C2 (ru) 2020-04-08
RU2535365C2 (ru) 2014-12-10
SG10201903161XA (en) 2019-05-30
EP2164993A4 (en) 2011-04-13
PT2164993T (pt) 2017-01-12
IL202401A0 (en) 2011-08-01
EP2164993B1 (en) 2016-09-21
EP3128015A2 (en) 2017-02-08
ES2612538T3 (es) 2017-05-17
EP3128015A3 (en) 2017-05-03
CN105586358B (zh) 2020-08-25
PL2164993T4 (pl) 2017-08-31
RU2014139904A3 (pt) 2018-06-28
SG10201509679XA (en) 2015-12-30
WO2008150814A8 (en) 2009-07-30
US20110217274A1 (en) 2011-09-08
CN101772580B (zh) 2015-11-25
PL2164993T3 (pl) 2017-08-31
CA2725953A1 (en) 2008-12-11
RU2009148666A (ru) 2011-07-10
EP2164993A2 (en) 2010-03-24
HUE030872T2 (en) 2017-06-28
IL241906A0 (en) 2015-11-30
JP2015077132A (ja) 2015-04-23
JP2010528613A (ja) 2010-08-26
AU2008260187A1 (en) 2008-12-11
IL241906B (en) 2021-07-29
RU2014139904A (ru) 2016-04-20
WO2008150814A2 (en) 2008-12-11
CN101772580A (zh) 2010-07-07
IL202401A (en) 2015-10-29
CN105586358A (zh) 2016-05-18
WO2008150814A3 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
BRPI0810949A2 (pt) "método de preparação de células multipotentes, auto-renovadoras, diferenciadoras ou resistentes a doenças, célula e vetor pra uso do método"
FR20C1033I2 (fr) Anticorps anti-cd79b, immuno-conjugues et procedes d'utilisation
IL204730A0 (en) Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
IL203029A (en) Rows of birds' immortal cells, their use and their process
GB2434205B (en) Module for preparing a biological sample, biochip-assembly and use of the module
SI2217578T1 (sl) (1,2,4)triazolo(1,5-a)piridinske in (1,2,4)triazolo(1,5-c)pirimidinske spojine in njihova uporaba
EP2189519A4 (en) CELL CULTURE INSTRUMENT AND CELL CUKLTURE PROCESS WITH THIS
BRPI0905712A2 (pt) "conjunto de células de bateria e método para construção do conjunto de células de bateria"
MY147394A (en) Pyridonecarboxamides, crop protection agents containing the same, method for production and use thereof
PT1973950E (pt) Anticorpos anti-epbh4 e métodos que os utilizam
EP2188834A4 (en) COMPOSITE, THERMAL INTERFACE MATERIAL CONTAINING THE COMPOSITE AND METHODS FOR THE PREPARATION AND USE THEREOF
IL202293A0 (en) 1,(,3)5-substituted imidazoles, their use in the treatment of hypertension and methods for their preparation
DK2254927T3 (da) Fugte- og dispergeringsmidler, disses fremstilling og anvendelse
EP1962635A4 (en) LOAD REDUCTION FOR SHOULDER AND USE THEREOF
DE602005005728D1 (de) Mikromanipulationssystem zum Gebrauch im Gesichtsfeld eines Mikroskops
ZA200808754B (en) Tetrahydronaphthaline derivatives, methods for the production and use hereof as anti-inflammatory agents
HK1147218A1 (en) Stem cell lines, their application and culture methods
PL1683840T3 (pl) Odporne na redukcję pigmenty oparte na ferrycie cynkowym, sposób ich wytwarzania i ich zastosowanie
ZA201202927B (en) N-allyl carbamate compounds and the use thereof,in particular for radiation-cured coatings
BRPI0807798A2 (pt) " aperfeiçoamento do crescimento celular ".
ZA200706646B (en) Brown algae cell lyophilisate, method for the obtention thereof
FR2913855B1 (fr) Agencement autoporte pour le demaillage, le brossage et le retournement de poches d'huitre
EP2157088A4 (en) FLUORESCENT INDOCYANINE DYES AND DERIVATIVES THEREOF FOR THE ANALYSIS OF BIOLOGICAL MACROMOLECULES
EP2107893A4 (en) ARTIFICIAL SEPARATE AORTA HEADLAP AND AN INTRODUCTION TO ITS MANUFACTURE
FR2880793B1 (fr) Prothese d'epaule

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL